Guselkumab Improves Tissue Health in Ulcerative Colitis
Adults with active ulcerative colitis showed sustained improvements in tissue inflammation over a three-year study period.
Updated on Oct. 30, 2026 in Diabetes
Live Poll
Do you trust that long-term medical study results reliably predict your own health outcomes?
Long-term data suggests guselkumab helps patients with moderately to severely active ulcerative colitis maintain improvements in tissue health. The findings, monitored over three years, offer new insights for those managing the condition.
Why it matters
Ulcerative colitis is a chronic inflammatory condition, and maintaining long-term tissue health is essential for reducing complications. These findings provide evidence on the potential for sustained histologic improvement over several years of treatment.
A three-year study of guselkumab in patients with ulcerative colitis found that 81.3% of those on a higher maintenance dose achieved histologic remission at 140 weeks. The research utilized Geboes scores to track improvements in tissue inflammation over the course of the trial.
The details
Guselkumab works by targeting specific inflammatory pathways involved in the progression of ulcerative colitis. In this study, patients received varying induction doses followed by maintenance therapy of either 100 mg every eight weeks or 200 mg every four weeks. Researchers performed biopsies at multiple intervals to assess tissue inflammation, confirming that most participants sustained positive histological changes throughout the three-year observation period.
Timeline
12 weeks marked the end of the initial induction phase for participants.
44 weeks was the point of the first follow-up biopsy.
92 weeks served as the time for the second follow-up biopsy.
140 weeks was the time of the final biopsy and assessment.
3 years was the total span of the study.
Health Landscape
The development of IL-23 inhibitor therapies for inflammatory bowel disease has significantly expanded treatment options for chronic gut inflammation. This study provides long-term evidence for targeting these pathways to achieve deeper tissue healing in patients with ulcerative colitis.
If you are managing moderately to severely active ulcerative colitis, these results highlight the importance of discussing long-term histologic goals with your gastroenterologist. Be sure to ask your care team about which maintenance therapy is appropriate based on your specific inflammatory profile.
The takeaway
Achieving and maintaining histologic remission is a key milestone for long-term health in those with ulcerative colitis. Talk to your physician about monitoring your tissue health through regular biopsies if you are currently using or considering biologic maintenance therapies.
Further reading
Learn more about the latest research and standard of care in the Diabetes section.
Source note: This article includes information reported by Healio.
Live Poll
Do you trust that long-term medical study results reliably predict your own health outcomes?
